Literature DB >> 4274706

Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.

A K Granerus, R Jagenburg, A Svanborg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4274706     DOI： 10.1007/bf00506633

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  11 in total

1.  Clinical analyses of factors influencing L-dopa treatment of Parkinson's syndrome.

Authors:  A K Granerus; G Steg; A Svanborg
Journal:  Acta Med Scand       Date:  1972 Jul-Aug

2.  Decarboxylation of orally administered L-dopa in the human digestive tract.

Authors:  J Bergmark; A Carlsson; A K Granerus; R Jagenburg; T Magnusson; A Svanborg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

Review 3.  [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].

Authors:  A Pletscher; G Bartholini; K F Gey; A Jenni
Journal:  Schweiz Med Wochenschr       Date:  1970-05-09

4.  L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.

Authors:  L Rivera-Calimlim; J P Morgan; C A Dujovne; J R Bianchine; L Lasagna
Journal:  Biochem Pharmacol       Date:  1971-11       Impact factor: 5.858

5.  Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral L-dopa.

Authors:  N S Sharpless; D S McCann
Journal:  Clin Chim Acta       Date:  1971-01       Impact factor: 3.786

6.  Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.

Authors:  J R Bianchine; L R Calimlim; J P Morgan; C A Dujuvne; L Lasagna
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

7.  Drug-induced changes of extracerebral dopa metabolism in man.

Authors:  R Tissot; G Bartholini; A Pletscher
Journal:  Arch Neurol       Date:  1969-02

8.  Absorption and metabolism of L-dopa by the human stomach.

Authors:  L Rivera-Calimlim; C A Dujovne; J P Morgan; L Lasagna; J R Bianchine
Journal:  Eur J Clin Invest       Date:  1971-05       Impact factor: 4.686

9.  Decrease in liver aromatic L-amino-acid decarboxylase produced by chronic administration of L-dopa.

Authors:  W Dairman; J G Christenson; S Udenfriend
Journal:  Proc Natl Acad Sci U S A       Date:  1971-09       Impact factor: 11.205

10.  Phenylalanine absorption and metabolism in Parkinsonian patients.

Authors:  A K Granerus; R Jagenburg; S Rödjer; A Svanborg
Journal:  Br Med J       Date:  1971-10-30
View more
  4 in total

1.  Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.

Authors:  M Murata; H Mizusawa; H Yamanouchi; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

4.  Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.

Authors:  Marina Senek; Dag Nyholm; Elisabet I Nielsen
Journal:  Eur J Clin Pharmacol       Date:  2018-06-07       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.